从“原料输出”到“终端产品”：福建明溪生物医药“链”上新能级

Core Viewpoint - The construction of the biopharmaceutical formulation industrial park in Mingxi, Fujian Province, is a significant step towards enhancing the local biopharmaceutical industry, focusing on high-end formulation enterprises and extending the value chain towards terminal products [1][2]. Group 1: Industrial Development - Mingxi has attracted 25 biopharmaceutical companies, creating a "string of pearls" effect in the industry [1]. - The region has established two distinctive industrial chains: one focusing on Taxus chinensis for anti-tumor raw materials and another on hexafluoroisopropanol and its derivatives [1]. - The collaboration among companies in the park has improved supply chain efficiency, reducing logistics costs and enhancing competitive advantages [1]. Group 2: Investment and Growth - By 2025, Mingxi aims to attract key projects in new business areas such as Marketing Authorization Holder (MAH) and Contract Research Organization (CRO), with a total investment of 2.78 billion yuan from six major projects [2]. - The accelerated construction of the biopharmaceutical formulation industrial park signifies a strategic shift from raw material output to terminal product output [2]. - The biopharmaceutical industry in Mingxi generated tax revenue of 293 million yuan, becoming a crucial driver for regional economic transformation and high-quality growth [2].